CORT Corcept Therapeutics Corp: Accounting Value per Share

Graphic logo of Corcept Therapeutics (CORT)

Corcept Therapeutics (CORT) produces exclusive treatments for correcting rare metabolic disorders, ensuring long-term profits through patent protection. The market price action of the securities shown below is at the level of 6.57. Corcept Therapeutics (CORT) relies on the commercial success of cortisol modulators that save patients with Cushing's syndrome. Its monopoly status in treating severe endocrine pathologies allows the business to independently determine high therapy costs.

Corcept Therapeutics Inc. (CORT): Share Book Value from 07/04/2022 to 10/27/2026

corcept.com - analytical breakdowns and key metrics (CORT)

- price and consensus price forecast:
Price Chart Corcept|CORT - Fair Value Consensus
- market capitalization data:
Market Valuation Corcept Therapeutics Incorporated|CORT - Aggregate Business Value
- book capitalization data:
Net Assets per Single Share Corcept Therapeutics|CORT - Net Asset Value|Market Capitalization to Book Value Ratio corcept.com|CORT - Aggregate Asset Value
- debt and liquidity data:
Total Debt to Capital Corcept Therapeutics|CORT - Long-Term Debt to Capital|Short-Term Debt to Equity Corcept Therapeutics Incorporated|CORT - Aggregate Debt Obligations|Debt to Book Capitalization Ratio Corcept Therapeutics Incorporated
Fundamental company valuation:Corcept - CORT
Manufactured products of Corcept Therapeutics Incorporated

Stress testing assets requires an analysis of the actual cost of capital without market distortions. For Corcept Therapeutics (CORT), protecting the patent portfolio from generics is critical to maintaining current margins. The book value per share reflects the portion of net assets belonging to the security holder after deducting all liabilities. The trend in book value per share demonstrates the speed of the issuer's material enrichment. Growth in this indicator confirms the business's resilience to legal risks.

Competitors of Corcept Therapeutics (CORT)

Net Assets per Single Share Ascendis Pharma Inc. (ASND)|Madrigal Corp (MDGL) - Accounting Value of a Share|RYTM - Accounting Value per Share|AKRO (akerotx.com) - Book Price of a Share|Net Assets per Single Share Metsera MTSR|Share Book Value MoonLake Immunotherapeutics AG|Crinetics Pharma (CRNX) - Book Value per Share|Accounting Value of a Share NewAmsterdam Pharma Corp (NAMS)|Book Value per Share SLNO (Soleno Therapeutics)|amicusrx.com - Book Value per Share|Net Assets per Single Share 89bio (ETNB)|AGIO: Accounting Value of a Share|GPCR (Structure Pharma) - Net Assets per Single Share|MiMedx Corp (MDXG) - Accounting Value per Share|RZLT (Rezolute, Inc.) - Book Value per Share|Book Value per Share lexpharma.com (LXRX)|MBX Biosciences (MBX) - Accounting Value per Share|Accounting Value of a Share ALT (Altimmune Inc)|Aardvark Therapeutics Corp - Net Assets per Single Share|Accounting Value per Share Sagimet Biosciences Inc SGMT|BIOA (BioAge Labs, Inc.) - Book Value per Share|biomeafusion.com (BMEA) - Net Asset Value per Share|QNCX - Accounting Value per Share|Fractyl Health Inc. (GUTS) - Book Price of a Share|VTVT (vTv Therapeutics, Inc.) - Book Value per Share|Book Value per Share Agape ATP Corp.|Book Value per Share Pluri Inc. (PLUR)|Net Assets per Single Share SYBX (synlogictx.com)|LPCN: Net Assets per Single Share|Matinas BioPharma Holdings, Inc. - Net Asset Value per Share|SPRB - Net Assets per Single Share|GLTO - Net Assets per Single Share|Carmell Corporation - Book Value per Share|LUMO (lumos-pharma.com) - Net Assets per Share|ONVO: Net Assets per Single Share|Net Assets per Share RDUS